FDA adverse event data shows semaglutide is associated with nearly twice the rate of vision impairment reports compared to other GLP-1 receptor agonists.
1.95x higher reporting vs. other GLP-1 drugsSemaglutide had nearly double the rate of vision impairment adverse event reports compared to other GLP-1 receptor agonists in the FDA database
What the researchers found
Semaglutide showed significantly elevated reporting of vision impairment compared to multiple drug classes in the FDA Adverse Event Reporting System (FAERS):
- vs. other GLP-1 receptor agonists: reporting odds ratio (rOR) 1.95 (95% CI 1.75–2.17, p < 0.0001)
- vs. DPP-4 inhibitors: rOR 2.46 (95% CI 2.12–2.86, p < 0.0001)
- vs. SGLT2 inhibitors: rOR 3.89 (95% CI 3.35–4.51, p < 0.0001)
- vs. metformin: rOR 2.23 (95% CI 1.90–2.62, p < 0.0001)
- vs. phentermine: rOR 1.57 (95% CI 1.07–2.31, p = 0.026)
- vs. orlistat: rOR 3.77 (95% CI 2.96–4.81, p < 0.0001)
Only topiramate had higher vision impairment reporting than semaglutide (rOR 0.30, p < 0.0001).
Why it matters
Semaglutide is one of the most widely prescribed medications globally, used by millions for type 2 diabetes and weight loss. If it carries an elevated risk of vision impairment, this has major public health implications. This signal from FDA adverse event data is an early warning that warrants rigorous clinical investigation, especially as the patient population using semaglutide continues to expand rapidly.
How the study worked
The researchers analyzed data from the FDA Adverse Event Reporting System (FAERS), a publicly available database of voluntary adverse event reports. They compared the frequency of vision impairment reports for semaglutide against other antidiabetic medications (other GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin) and weight loss medications (phentermine, orlistat, topiramate). The main outcome measure was the reporting odds ratio (rOR), which compares how often a side effect is reported for one drug versus another.
What this study cannot tell us
FAERS data is based on voluntary reports, not systematic surveillance, so it's subject to reporting bias — popular drugs like semaglutide may receive disproportionate attention. The analysis cannot establish causation, only an association in reporting patterns. The study uses reporting odds ratios, not absolute risk rates, so the actual clinical risk of vision impairment cannot be determined. Confounding factors like underlying diabetes severity, which itself causes vision problems, were not controlled for.
How to read the evidence
This is a pharmacovigilance study using FDA adverse event reporting data. While it reveals an important safety signal, FAERS analyses are observational, subject to reporting bias, and cannot establish causation. Prospective clinical studies are needed to confirm the association.
When this study was published
Published in 2025, this is a very recent study addressing a timely concern given the explosive growth in semaglutide prescriptions worldwide.
The bigger picture
This study adds to a growing body of pharmacovigilance signals around GLP-1 receptor agonists and ocular health. As semaglutide and similar drugs become some of the most prescribed medications worldwide for both diabetes and obesity, understanding their full safety profile — including potential effects on vision — is critical. This finding also raises the question of whether the vision impairment signal is specific to semaglutide or shared across GLP-1 agonists at different rates.
Questions still open
- Is the elevated vision impairment signal specific to semaglutide, or does it reflect a class effect of GLP-1 receptor agonists at different intensities?
- What specific types of vision impairment are being reported — is this related to diabetic retinopathy progression, or a novel mechanism?
- Does the risk of vision impairment differ between semaglutide used for diabetes versus weight loss in non-diabetic patients?
Common questions
Does this study prove semaglutide causes vision problems?
Should I stop taking semaglutide because of these findings?
Read the original research
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.
BMC medicine, 23(1), 203
Citation
Massy, Marine; Marti, Stefanie; Hammer, Helly; Hoepner, Robert. (2025). Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.. BMC medicine, 23(1), 203. https://doi.org/10.1186/s12916-025-04031-z